Autonomic effects of spironolactone and MR blockers in heart failure

Heart Failure Reviews

Volumn 10, Issue 1, 2005, Pages 63-69

  Davies, Justine I ^a   Witham, Miles D ^a   Struthers, Allan D ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Aldosterone; Autonomic; Heart failure; Spironolactone

Indexed keywords

(3 IODOBENZYL)GUANIDINE; MINERALOCORTICOID ANTAGONIST; NORADRENALIN; SPIRONOLACTONE;

ANTIHYPERTENSIVE ACTIVITY; AUTONOMIC DYSFUNCTION; BLOOD VESSEL TONE; CONGESTIVE HEART FAILURE; DRUG MECHANISM; HEART RATE; HEART RATE VARIABILITY; HEART SCINTISCANNING; HORMONE ACTION; HORMONE INHIBITION; HUMAN; INTRINSIC SYMPATHOMIMETIC ACTIVITY; NORADRENALIN BLOOD LEVEL; PRESSORECEPTOR REFLEX; QT INTERVAL; RECEPTOR BLOCKING; REVIEW;

ALDOSTERONE; ALDOSTERONE ANTAGONISTS; AUTONOMIC NERVOUS SYSTEM; DIURETICS; HEART FAILURE, CONGESTIVE; HEART RATE; HUMANS; RECEPTORS, ALDOSTERONE; SPIRONOLACTONE;

EID: 21244470282     PISSN: 13824147     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10741-005-2350-4     Document Type: Review

References (50)

1. Yoshikawa T, Baba A, Akaishi M, Mitamura H, Ogawa S, Suzuki M, et al. Neurohumoral activations in congestive heart failure: Correlations with cardiac function, heart rate variability, and baroreceptor sensitivity. Am Heart J 1999;137(4 Pt 1):666-671. 1:STN:280:DyaK1M7pvFSqtQ%3D%3D
2. Hasking GJ, Esler MD, Jennings GL, Burton D, Johns JA, Korner PI. Norepinephrine spillover to plasma in patients with congestive heart failure: Evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation 1986;73(4):615-621. 1:STN:280:BimC3svgs1M%3D
3. Amorim DS, Dargie HJ, Heer K, Brown M, Jenner D, Olsen EG, et al. Is there autonomic impairment in congestive (dilated) cardiomyopathy? Lancet 1981;1(8219):525-527. 1:STN:280:Bi6C2s7nsVM%3D
4. Eckberg DL, Drabinsky M, Braunwald E. Defective cardiac parasympathetic control in patients with heart disease. N Engl J Med 1971;285(16):877-883. 1:STN:280:CS2D38vntFw%3D
5. Nolan J, Batin PD, Andrews R, Lindsay SJ, Brooksby P, Mullen M, et al. Prospective study of heart rate variability and mortality in chronic heart failure: Results of the United Kingdom heart failure evaluation and assessment of risk trial (UK-heart). Circulation 1998;98(15):1510-1516. 1:STN:280:DyaK1cvktlCqug%3D%3D
6. Francis GS, Cohn JN, Johnson G, Rector TS, Goldman S, Simon A. Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II. The V-HeFT VA Cooperative Studies Group. Circulation 1993;87(suppl6):VI40- VI48. 1:STN:280:ByyB2s3ktlc%3D
7. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984;311(13):819-823. 1:STN:280:BiuB1MrkslQ%3D
8. Merlet P, Valette H, Dubois-Rande JL, Moyse D, Duboc D, Dove P, et al. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med 1992;33(4):471-477. 1:STN:280:By2B3c3pvVI%3D
9. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353(9169):2001-2007.
10. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial. Lancet 1999;353(9146):9-13.
11. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996;334(21):1349-1355. 10.1056/NEJM199605233342101
12. Piepoli MF, Davos C, Francis DP, Coats AJ. Exercise training meta-analysis of trials in patients with chronic heart failure (ExTraMATCH). BMJ 2004;328(7433):189. 1:STN:280:DC%2BD2c%2FjvV2ntw%3D%3D
13. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341(10):709-717. 10.1056/ NEJM199909023411001
14. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348(14):1309-1321. 10.1056/NEJMoa030207
15. Heart rate variability: Standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Circulation 1996;93(5):1043-1065.
16. Pomeranz B, Macaulay RJ, Caudill MA, Kutz I, Adam D, Gordon D, et al. Assessment of autonomic function in humans by heart rate spectral analysis. Am J Physiol 1985;248(1 Pt 2):H151-H153. 1:STN:280:BiqC3MblslE%3D
17. Yee KM, Pringle SD, Struthers AD. Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure. J Am Coll Cardiol 2001;37(7):1800-1807. 1:CAS:528:DC%2BD3MXltVGhsL0%3D
18. Casolo GC, Stroder P, Sulla A, Chelucci A, Freni A, Zerauschek M. Heart rate variability and functional severity of congestive heart failure secondary to coronary artery disease. Eur Heart J 1995;16(3):360-367. 1:STN:280:ByqA3cbisFQ%3D
19. Bleske BE, Chung HS, DiMagno M, Nicklas JM. Diurnal variation in plasma norepinephrine in patients with heart failure. Pharmacotherapy 1999;19(8):984-988. 1:STN:280:DyaK1MzotFOksQ%3D%3D
20. Rose CP, Burgess JH, Cousineau D. Reduced aortocoronary sinus extraction of epinephrine in patients with left ventricular failure secondary to long-term pressure or volume overload. Circulation 1983;68(2):241-244. 1:STN:280:BiyB3szhs1Y%3D
21. Petch MC, Nayler WG. Uptake of catecholamines by human cardiac muscle in vitro. Br Heart J 1979;41(3):336-339. 1:STN:280:CSaC2crhtF0%3D
22. Lin LY, Lai LP, Lin JL, Du CC, Shau WY, Chan HL, et al. Tight mechanism correlation between heart rate turbulence and baroreflex sensitivity: Sequential autonomic blockade analysis. J Cardiovasc Electrophysiol 2002;13(5):427-431. 12030522
23. Davies LC, Francis DP, Ponikowski P, Piepoli MF, Coats AJ. Relation of heart rate and blood pressure turbulence following premature ventricular complexes to baroreflex sensitivity in chronic congestive heart failure. Am J Cardiol 2001;87(6):737-742. 1:STN:280:DC%2BD3M7mtlyjug%3D%3D
24. Roach D, Koshman ML, Duff H, Sheldon R. Induction of heart rate and blood pressure turbulence in the electrophysiologic laboratory. Am J Cardiol 2002;90(10):1098-1102. 12423710
25. Schmidt G, Malik M, Barthel P, Schneider R, Ulm K, Rolnitzky L, et al. Heart-rate turbulence after ventricular premature beats as a predictor of mortality after acute myocardial infarction. Lancet 1999;353(9162):1390-1396. 10.1016/S0140-6736(98)08428-1
26. Grimm W, Schmidt G, Maisch B, Sharkova J, Muller HH, Christ M. Prognostic significance of heart rate turbulence following ventricular premature beats in patients with idiopathic dilated cardiomyopathy. J Cardiovasc Electrophysiol 2003;14(8):819-824. 12890042
27. Koyama J, Watanabe J, Yamada A, Koseki Y, Konno Y, Toda S, et al. Evaluation of heart-rate turbulence as a new prognostic marker in patients with chronic heart failure. Circ J 2002;66(10):902-907. 12381082
28. Ferguson DW, Berg WJ, Sanders JS. Clinical and hemodynamic correlates of sympathetic nerve activity in normal humans and patients with heart failure: Evidence from direct microneurographic recordings. J Am Coll Cardiol 1990;16(5):1125-1134. 1:STN:280:By6D3snkvVw%3D
29. Grassi G, Colombo M, Seravalle G, Spaziani D, Mancia G. Dissociation between muscle and skin sympathetic nerve activity in essential hypertension, obesity, and congestive heart failure. Hypertension 1998; 31(1):64-67. 1:STN:280:DyaK1c7gvFCntA%3D%3D
30. Notarius CF, Butler GC, Ando S, Pollard MJ, Senn BL, Floras JS. Dissociation between microneurographic and heart rate variability estimates of sympathetic tone in normal subjects and patients with heart failure. Clin Sci (Lond) 1999;96(6):557-565. 1:STN:280:DyaK1M3mvV2ktw%3D%3D
31. Barr CS, Naas A, Freeman M, Lang CC, Struthers AD. QT dispersion and sudden unexpected death in chronic heart failure. Lancet 1994;343(8893):327-329. 10.1016/S0140-6736(94)91164-9
32. Wong KY, Mac Walter RS, Douglas D, Fraser HW, Ogston SA, Struthers AD. Long QTc predicts future cardiac death in stroke survivors. Heart 2003;89(4):377-381. 1:STN:280:DC%2BD3s7isFKgtg%3D%3D
33. Can I, Aytemir K, Kose S, Oto A. Physiological mechanisms influencing cardiac repolarization and QT interval. Card Electrophysiol Rev 2002;6(3):278-281. 12114852
34. Brooksby P, Batin PD, Nolan J, Lindsay SJ, Andrews R, Mullen M, et al. The relationship between QT intervals and mortality in ambulant patients with chronic heart failure. The united kingdom heart failure evaluation and assessment of risk trial (UK-HEART). Eur Heart J 1999;20(18):1335-1341. 1:STN:280:DyaK1MzptlCmug%3D%3D
35. MacFadyen RJ, Barr CS, Struthers AD. Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res 1997;35(1):30-34. 10.1016/S0008-6363(97)00091-6
36. Yee KM, Struthers AD. Aldosterone blunts the baroreflex response in man. Clin Sci (Lond) 1998;95(6):687-692. 1:CAS:528:DyaK1MXmtVylsQ%3D%3D
37. Barr CS, Struthers AD. Aldosterone blunts the reflex baroceptor response to noradrenaline in healthy man. Br Heart J 1994;71:96. 8297707
38. Ferrari A, Gregorini L, Ferrari MC, Preti L, Mancia G. Digitalis and baroreceptor reflexes in man. Circulation 1981;63(2):279-285. 1:STN:280:Bi6D1cfmsFY%3D
39. Lim PO, Farquharson CA, Shiels P, Jung RT, Struthers AD, MacDonald TM. Adverse cardiac effects of salt with fludrocortisone in hypertension. Hypertension 2001;37(3):856-861. 1:CAS:528:DC%2BD3MXitFegtLg%3D
40. Korkmaz ME, Muderrisoglu H, Ulucam M, Ozin B. Effects of spironolactone on heart rate variability and left ventricular systolic function in severe ischemic heart failure. Am J Cardiol 2000;86(6):649-653. 1:CAS:528:DC%2BD3cXmt1Wqt7o%3D
41. Muller JE, Tofler GH, Stone PH. Circadian variation and triggers of onset of acute cardiovascular disease. Circulation 1989;79(4):733-743. 1:STN:280:BiaC28fmvVY%3D
42. Moser DK, Stevenson WG, Woo MA, Stevenson LW. Timing of sudden death in patients with heart failure. J Am Coll Cardiol 1994;24(4):963-967. 1:STN:280:ByqD3MrksFc%3D
43. Farquharson CA, Struthers AD. Increasing plasma potassium with amiloride shortens the QT interval and reduces ventricular extrasystoles but does not change endothelial function or heart rate variability in chronic heart failure. Heart 2002;88(5):475-480. 1:CAS:528:DC%2BD38XosFKhu7s%3D
44. Macdonald JE, Kennedy N, Struthers AD. Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment. Heart 2004;90(7):765-770. 1:CAS:528:DC%2BD2cXmtlCgsLg%3D
45. Kinugawa T, Ogino K, Kato M, Furuse Y, Shimoyama M, Mori M, et al. Effects of spironolactone on exercise capacity and neurohormonal factors in patients with heart failure treated with loop diuretics and angiotensin-converting enzyme inhibitor. Gen Pharmacol 1998;31(1):93-99. 1:CAS:528:DyaK1cXjtVejt74%3D
46. Schohn DC, Jahn HA, Pelletier BC. Dose-related cardiovascular effects of spironolactone. Am J Cardiol 1993;71(3):40A-45A. 1:STN:280:ByyC3srhtlE%3D
47. Barr CS, Lang CC, Hanson J, Arnott M, Kennedy N, Struthers AD. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 1995;76(17):1259-1265. 10.1016/ S0002-9149(99)80353-1
48. Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, et al. Effect of spironolactone on cardiac sympathetic nerve activity and left ventricular remodeling in patients with dilated cardiomyopathy. J Am Coll Cardiol 2003;41(4):574-581. 10.1016/S0735-1097(02)02855-3
49. Akbulut M, Ozbay Y, Ilkay E, Karaca I, Arslan N. Effects of spironolactone and metoprolol on QT dispersion in heart failure. Jpn Heart J 2003;44(5):681-692. 1:CAS:528:DC%2BD3sXpt1eisL4%3D
50. Davies JI, Band M, Morris A, Struthers AD. Spironolactone impairs endothelial function and heart rate variability in patients with Type 2 diabetes. Diabetologia 2004;47(10):1687-1694. 1:CAS:528:DC%2BD2cXpsFKrtrc%3D